[DT Membership Roster] [DT Meeting Rosters]

The Developmental Therapeutics [DT] Study Section reviews applications addressing the experimental therapy of neoplastic diseases in in vitro systems and in vivo model systems, including some early-stage, pilot clinical trials. The major emphasis of this study section is on the rational development of novel therapeutic strategies that have a significant potential for early translation to the clinic. Specific areas covered by DT:

• Evaluation of drug-delivery strategies (including nanoparticles, liposomes and other delivery vehicles) and gene therapy approaches involving non-immunologic targets for the treatment of cancer.
• Translational studies of novel antineoplastic agents and pre-clinical drug toxicity, pharmacokinetic/pharmacodynamic and biomarker studies of anticancer agents.
• Development of anti-angiogenic therapeutic strategies and rational combinations of cytotoxic drugs with novel agents including those targeting: growth factors, signaling, cell cycle regulation, angiogenic, and differentiation pathways.
• Development and application of mathematical and computational methods for the investigation of combination chemotherapy using small molecules and other modalities.
• Therapeutic approaches involving biologic response modifiers, (including cytokines, and hormonal agents) either alone or in combination with novel or conventional drugs for cancer treatment.
• Early-stage, pilot clinical trials of novel anticancer therapeutic and drug-delivery strategies involving pharmacokinetic, pharmacodynamic, toxicologic, or pharmacogenomic endpoints

The study sections with most closely related areas of similar science listed in rank order are:

Basic Mechanisms of Cancer Therapeutics Study Section [BMCT] 
Gene and Drug Delivery Systems Study Section [GDD] 
Cancer Immunopathology and Immunotherapy Study Section [CII] 
Drug Discovery and Molecular Pharmacology Study Section [DMP] 
Clinical Oncology Study Section [CONC]